This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Idera Pharmaceuticals, Inc.
Drug Names(s): IMO-3100
Deal Structure: IMO-3100 is a DNA-based antagonist of Toll-like Receptor (TLR) 7 and TLR9, which has been shown in preclinical assays to suppress immune responses mediated through TLR7 and TLR9, including induction of interferon-alpha, TNF-alpha, IP-10, IL-6, and activation of B cells.
Additional information available to subscribers only: